

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Varenicline 1 mg Tablet (DIN 02419890) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the Least Cost Alternative (LCA) price policy will be reapplied to the following grouping effective **October 28, 2021**. The following grouping was removed from the Critical Supply Product List **September 28, 2021**.

VARENICLINE TARTRATE

1 MG TABLET

00002419890	APO-VARENICLINE	APX	\$ 0.9235
00002426234	TEVA-VARENICLINE	TEV	\$ 0.9235
00002291185	CHAMPIX	PFI	\$ 1.8432

Alberta Blue Cross has been advised by Omega Laboratories Limited that the shortage for Octreotide Acetate Omega 100 mcg/ml Injection (DIN 02248640) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 18, 2021**. The following grouping was removed from the Critical Supply Product List **October 19, 2021**.

OCTREOTIDE ACETATE

100 MCG / ML INJECTION

00002248640	OCTREOTIDE ACETATE OMEGA	OMG	\$ 7.5660
00000839205	SANDOSTATIN	NOV	\$ 9.7135

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php